Medicare Drug Price Negotiation Heads to 2028: What Beneficiaries Should Know

Most people assume Medicare’s drug price negotiations are already done and the savings are locked in. They’re not. The real work, getting those negotiated prices from paper agreements into your hands at the pharmacy counter or your doctor’s office, is just getting started. And right now, in the summer of 2026, we’re watching that machinery get built in real time.

On July 16, 2026, the Centers for Medicare & Medicaid Services (CMS, the federal agency that runs Medicare) released draft guidance with a specific and unprecedented focus: exactly how drug manufacturers must implement Medicare’s negotiated Maximum Fair Prices (MFPs) when they take effect in 2028. This isn’t a press release about future savings. It’s a technical blueprint covering both drugs you pick up at the pharmacy and drugs your doctor administers in an office or clinic setting. According to the CMS fact sheet on the MFP draft guidance, this is the first time the government has mapped the operational mechanics for both of those delivery channels together. Public comments are due August 17, 2026, and a final rule is expected this fall.

If you’re a Medicare beneficiary, a caregiver, or someone who’s been watching this program and wondering when it actually affects your wallet, this is the moment to pay attention. The 2028 prices are being negotiated right now, and the rules governing how those prices reach you are being written right now.

What “Maximum Fair Prices” Actually Means for You

MFP is the term CMS uses for the negotiated price a manufacturer must charge for a selected drug under the Inflation Reduction Act (IRA), the 2022 law that authorized Medicare to negotiate drug prices for the first time in the program’s history. Before the IRA, it was actually illegal for Medicare to negotiate drug prices directly with manufacturers. That’s changed.

Here’s what the July 16 draft guidance addresses that genuinely surprised me when I read through it: the logistics of implementation are more complicated than I’d assumed. It’s not simply that a drug gets a new price tag. Manufacturers have to ensure that the MFP flows correctly through a web of pharmacy benefit managers (PBMs, the middlemen who process drug claims), health plans, pharmacies, and physician practices. The draft guidance spells out manufacturer obligations for each of these channels, which tells you something important: CMS has learned from the first round of negotiations that the gap between a negotiated price and a price a patient actually sees can be wide.

For you as a beneficiary, the practical implication is that you’ll want to confirm with your plan, starting in late 2026 when prices are released publicly, that the drugs on your list are covered at the negotiated rate and that your pharmacy is set up to apply it correctly.

The 2028 Negotiation Cycle, Explained

Helpful resource: OMRON Platinum Blood Pressure Monitor Upper Arm is a top-rated option for this. (As an Amazon Associate this site earns from qualifying purchases.)

The IRA set up a rolling negotiation schedule, and we’re currently in the 2026 negotiating cycle for drugs that will have price applicability in 2028. Up to 15 Part D (prescription drug coverage) and/or Part B (medical insurance, which covers doctor-administered drugs) medications are being negotiated right now. The first round, covering 10 drugs, produced prices effective January 1, 2026. This 2028 cycle expands the program’s reach.

Here’s how the timeline looks for the drugs being negotiated now:

What this means practically: you should have about a full year to review which drugs are covered at negotiated prices before those prices actually hit. That’s a meaningful window, and I’d encourage anyone on an expensive specialty drug to mark November 2026 on their calendar and check Medicare.gov or call 1-800-MEDICARE when those prices drop.

The Proposed Rule: New Guardrails and What They’re Trying to Prevent

The first-ever proposed rule for the IRA Medicare Drug Price Negotiation Program was published in the Federal Register on June 16, 2026, a few weeks before the July guidance. As analyzed by Holland & Knight, the rule addresses something that policy watchers have been worried about since the program launched: manufacturers finding creative ways to restructure their products to dodge negotiation eligibility altogether.

CMS is proposing new program integrity measures specifically aimed at preventing this. I’ll be honest, the details here are technical, but the bottom-line concern is real. If a manufacturer can reformulate a drug, rename it, or change its delivery mechanism just enough to reset its eligibility clock, the savings never materialize for patients. The proposed rule also expands CMS’s enforcement authorities to address these scenarios.

There’s also a protection being proposed for small biotechnology companies. The IRA included a statutory exemption for small biotech firms that was always time-limited. That exemption expires after the 2028 applicability year, and CMS is now proposing new protections to fill that gap. The research here is mixed on whether these protections are sufficient, and industry groups are likely to weigh in heavily before the August 17 comment deadline. If you or your prescriber has strong feelings about a specific drug, the public comment process is open to anyone at regulations.gov.

The Doctor’s Office Piece: Part B Drugs Are New Territory

Most of the early public conversation about Medicare drug negotiation focused on Part D, the prescription drug benefit. What’s newer, and gets less attention, is that Part B drugs are also in scope. Part B covers drugs administered in a clinical setting: think cancer infusions, certain biologics (complex drugs made from living cells) given by injection, and other therapies your physician applies in their office.

The July 16 draft guidance explicitly addresses how MFPs must reach physician practices and outpatient settings, not just pharmacies. As iPharmacenter reported, CMS is laying out compliance pathways for these clinical channels that didn’t exist before. This matters because Part B drug costs can be staggering, sometimes tens of thousands of dollars per treatment, and physicians are reimbursed differently for these drugs than pharmacies are for retail medications.

If you receive a physician-administered therapy covered under Part B, ask your doctor’s billing office whether that drug is on the negotiation list. Starting in late 2026, when negotiated prices are published, this becomes a concrete question with a concrete answer.

What to Watch For in the Coming Months

The next few months are genuinely the most active period this program has seen. The August 17 comment deadline matters: CMS does read public comments and they sometimes change proposed rules based on them. A final rule is expected in fall 2026. And before November 30, 2026, you’ll be able to see the actual negotiated prices for up to 15 more drugs.

If you want to stay current, bookmark Medicare.gov’s drug price negotiation page and sign up for CMS email updates. If you take a high-cost medication and want to know whether it might be selected for a future negotiation cycle, that February 1, 2027, deadline for announcing 2029 drugs is your next signpost. And as always, talk to a licensed Medicare counselor or your State Health Insurance Assistance Program (SHIP), a free counseling service available in every state, before making any coverage decisions. This program is still evolving, and personalized guidance from someone who knows your situation is worth seeking out.

Sources

• CMS – Manufacturer Effectuation of MFP Draft Guidance for 2028 Medicare Drug Price Negotiation (July 16, 2026)
• CMS – Regulations, Guidance, and Policy Documents (Medicare Drug Price Negotiation Program) (July 16, 2026)
• Holland & Knight – CMS Issues First Proposed Rule for IRA Medicare Drug Price Negotiation (June 18, 2026)
• iPharmacenter – CMS Outlines Operational Path for 2028 Maximum Fair Price Compliance (July 20, 2026)
• Federal Register – Medicare Drug Price Negotiation Program and Medicare Prescription Drug Benefit Program (Proposed Rule) (June 16, 2026)

Photo: Deise Elen via Pexels

This article is for informational purposes only. Medicare rules change annually. Always verify current plan details at Medicare.gov or by calling 1-800-MEDICARE (1-800-633-4227). This site does not sell insurance or recommend specific plans.

Recommended Resources

Disclosure: As an Amazon Associate, we earn a small commission from qualifying purchases at no extra cost to you. We only recommend products that genuinely support the topics covered in this article.

• Medicare For Dummies (~$22), The definitive consumer guide to Medicare, enrollment windows, Part A/B/C/D, and supplement plans.
• Get What’s Yours for Medicare (~$17), Maximize your Medicare benefits and minimize out-of-pocket costs. Covers Part D drug coverage gaps and Medigap in depth.